组合式药物基因组学方法在重性抑郁障碍中的临床验证:一项观察性前瞻性随机、参与者和评估者设盲的对照试验(PANDORA试验)
PANDORA是一项前瞻性、参与者和评估者设盲的随机对照观察性试验,计划纳入300例因当前治疗失败或出现不良反应而需换用新抗抑郁药的重性抑郁障碍患者,随机分为遗传检测指导组(TGTG)与常规治疗组(TAU),主要结局为抑郁症状减轻,于基线及第4、8、12周评估。该研究旨在验证非商业药物基因组学检测能否改善自然队列中的治疗结局,并识别与治疗无反应或副作用相关的新遗传变异。
要点
- PANDORA试验验证非商业药物基因组学检测能否改善重性抑郁障碍患者的结局。
- 患者随机分为遗传检测指导组(TGTG)与常规治疗组(TAU),主要结局为抑郁症状减轻。
- 评估时间点为基线及第4、8、12周,同时评估社会功能等次要结局。
核心结论
- 本研究旨在对组合式药物基因组学检测在意大利重性抑郁障碍患者队列中进行临床验证,并保持倡导许可的独立性。
- 该研究是首个在重性抑郁障碍自然队列中探讨非商业药物基因组学检测能否改善结局的随机对照临床试验。
- 识别与治疗无反应或副作用相关的新遗传变异将改进检测效能并进一步节省成本。
研究设计与样本
- 前瞻性、参与者和评估者设盲、随机、对照的临床观察性试验,计划纳入300例转诊至精神科服务、因当前治疗失败和/或出现不良反应而需接受新抗抑郁药治疗的重性抑郁障碍患者。
- 符合条件者随机分为遗传检测指导组(TGTG)或常规治疗组(TAU),所有受试者以口腔拭子采集DNA。
- 主要结局为抑郁症状减轻;次要结局包括评估重性抑郁障碍症状和社会功能结局的一系列量表。
- 评估在基线和第4、8、12周四个时间点进行。
- 试验注册号ClinicalTrials.gov NCT04615234,注册日期2020年11月4日。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Major depressive disorder (MDD) is a common, chronic, debilitating mood disorder that causes serious functional impairment and significantly decreased quality of life. Pharmacotherapy represents the first-line treatment option; however, only approximately one third of patients respond to the first treatment because of the ineffectiveness or side effects of antidepressants. Precision medicine in psychiatry might offer clinicians the possibility to tailor treatment according to the best possible evidence of efficacy and tolerability for each subject. In this context, our study aims to carry out a clinical validation of a combinatorial pharmacogenomics (PGx) test in an Italian MDD patient cohort with advocacy license independence. METHODS: Our study is a prospective participant- and rater-blinded, randomized, controlled clinical observational trial enrolling 300 MDD patients who are referred to psychiatric services to receive a new antidepressant due to the failure of their current treatment and/or the onset of adverse effects. Eligible participants are randomized to the TGTG group (Treated with Genetic Test Guide) or TAU group (Treated as Usual). For all subjects, DNA is collected with a buccal brush. The primary outcome is the reduction in depressive symptomatology. The secondary outcomes involve a range of scales that assess MDD symptoms and social functioning outcomes. The assessment is performed at four timepoints: baseline and 4, 8, and 12 weeks. DISCUSSION: This project represents the first randomized controlled clinical trial to investigate whether a non-commercial PGx test improves outcomes in an MDD naturalistic cohort. Moreover, the identification of new genetic variants associated with non-response or side effects will improve the efficacy of the test, leading to further cost-saving. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT04615234. Registered on November 4, 2020.
引用
- Minelli A, Barlati S, Vitali E, et al. Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA trial). Trials. 2021. PMID: 34895291. doi:10.1186/s13063-021-05775-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。